Beike BioA response was made to the regulatory inquiry letter regarding information disclosure in the 2025 semi-annual report, mentioning the reasons for the decline in sales of shingles vaccine.

　　In the first half of 2025, the company's operating income was 285 million yuan, a year-on-year decrease of 53.93%; the net profit was -73.5734 million yuan, turning from profit to loss year-on-year. The company disclosed that the decline in performance was mainly due to the decline in sales of shingles vaccine.

　　The announcement showed that during the reporting period, the company's sales volume of shingles vaccine was -17,300 doses, with sales revenue of -65.2266 million yuan.

　　Beike Bio believes that factors such as product price structure, vaccination demand, low disease awareness, insufficient consumption willingness of the applicable group, and vaccine hesitation affect the product revenue.

　　The company stated in its response that during the reporting period, sales of herpes zoster vaccines decreased year-over-year, leading to lower revenue. This was due to factors such as recipients' disease awareness and willingness to consume the vaccine. Some herpes zoster vaccines, for which revenue had been recognized in previous years, expired and were not sold, leading to returns and reduced revenue. To increase vaccination coverage and promote public welfare programs, the company implemented discounts of 30% to 80% on some products. This led to lower unit prices for some products shipped this year, as well as for products for which revenue had been recognized in previous years but not actually administered, resulting in lower revenue.

　　The company further explained that during the reporting period, the sales price of the shingles vaccine consisted of two types: the main price (tax included) of 1,369 yuan per dose, and a discounted price (30% to 80% off the regular price) adopted for a public welfare program. During the reporting period, 86,500 doses of the shingles vaccine were sold at the main price (tax included) of 1,369 yuan per dose, generating approximately 115 million yuan in operating revenue. The company also sold 43,900 doses at a discounted price (30% to 80% off the regular price) through a public welfare program, generating 29.4988 million yuan in operating revenue. Products recognized as revenue in previous years but not actually administered were sold at the public welfare program price, resulting in a reduction of 13.4773 million yuan in operating revenue. Due to factors such as recipients' disease awareness and willingness to consume the vaccine, some shingles vaccines recognized as revenue in previous years expired and were not sold, resulting in 147,700 returns, resulting in a reduction of 196 million yuan in revenue.